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Abstract
Objectives—If approved for use in young males in the United States, prophylactic human
papillomavirus (HPV) vaccine may reduce the incidence of HPV-related disease in vaccinated
males and their sexual partners. We aimed to characterise heterosexual men’s willingness to get
HPV vaccine and identify correlates of vaccine acceptability.
Methods—Participants were from a national sample of heterosexual men (n=297) aged 18–59 y
from the United States who were interviewed in January 2009. We analysed data using
multivariate logistic regression.
Results—Most men had not heard of HPV prior to the study or had low HPV knowledge (81%;
239/296). Most men had heard of HPV vaccine prior to the study (63%; 186/296) and 37%
(109/296) were willing to get HPV vaccine. Men were more willing to get vaccinated if they
reported higher perceived likelihood of getting HPV-related disease (OR 1.80, 95% CI 1.02 to
3.17), perceived HPV vaccine effectiveness (OR 1.86, 95% CI 1.22 to 2.83) or anticipated regret if
they did not get vaccinated and an HPV infection later developed (OR 2.01, 95% CI 1.40 to 2.89).
Acceptability was also higher among men who thought (OR 9.02, 95% CI 3.45 to 23.60) or who
were unsure (OR 2.67, 95% CI 1.30 to 5.47) if their doctor would recommend they get HPV
vaccine if licenced for males.
Conclusions—Men had low HPV knowledge and were moderately willing to get HPV vaccine.
These findings underscore the need for HPV educational efforts for men and provide insight into
some of the factors that may affect the HPV vaccination decision making process among men.
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Human papillomavirus (HPV) infection is common among men, with most studies reporting
prevalence levels of at least 20%.12 Approximately 75% of infections clear within 1 year,3
but men infected with HPV still face potentially severe health consequences. Oncogenic
HPV types (mainly types 16 and 18) may be responsible for up to 63% of oropharyngeal
cancers, 93% of anal cancers and 36% of penile cancers in the United States.4 Genital warts
are primarily attributable to infection with nononcogenic HPV types 6 and 11.5 Men
infected with HPV also put their female partners at increased risk for cervical disease.67
The United States has approved a quadrivalent HPV vaccine against types 6, 11, 16 and 18
for use in females aged 9–26 y to protect against cervical cancer and genital warts.8
Research suggests the vaccine may also reduce the incidence of persistent HPV infection
and genital warts among young men not infected with HPV types included in the vaccine.910
Statistical models differ as to whether vaccinating males against HPV will be cost-effective,
with more favourable conclusions reached when models accounted for diseases in addition
to cervical cancer in females or HPV-related diseases in males.1112 A US Food and Drug
Administration advisory panel recently recommended approving HPV vaccine for males
aged 9–26 y,13 although formal Food and Drug Administration approval has not yet
occurred.
For optimal public health benefit, HPV vaccination should occur before first sexual
intercourse.14 The population-level benefit of vaccinating adult men against HPV is
unknown and may not outweigh the costs. However, if HPV vaccine is licenced for
adolescent males, adult men will still have to decide whether ‘off-label’ vaccination offers
potential individual benefits that outweigh out-of-pocket costs. Similar off-label HPV
vaccination is already occurring among adult women in the United States.15 Thus, it is of
interest to examine HPV vaccine acceptability among adult men. HPV vaccine acceptability
among college students or other convenience samples of adult men has previously ranged
from modest (33%–48%) to relatively high (78%).16–18
In this study, we aimed to characterise correlates of HPV vaccine acceptability among a
national sample of heterosexual men. We focused on constructs from health behaviour




We interviewed men aged 18–59 y who were members of an existing national panel of US
households maintained by Knowledge Networks (Menlo Park, California, USA) in January
2009. Knowledge Networks identified prospective panel members using list-assisted,
random-digit dialing. Households containing one or more panel members receive free
internet access for completing multiple internet-based surveys each month. Panel members
with existing computer and internet access accumulate points for completing surveys, which
can be redeemed for small cash payments.
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About 70% (609/874) of men invited to participate completed this cross-sectional, online
survey.20 We report data from self-identified heterosexual men (n=297), as results for the
oversample of gay and bisexual men have been reported elsewhere.21 The Institutional
Review Board at the University of North Carolina approved the study.
Measures
The University of North Carolina Men’s Health Survey is available online at http://
www.unc.edu/~ntbrewer/hpv.htm. We developed survey items based on our previous HPV
vaccine research with women, parents and healthcare providers.22–24 We cognitively tested
the survey with 28 men to gain an initial sense of item clarity and men’s familiarity with
HPV and HPV vaccine. After refining the survey, we further tested it with eight additional
men prior to the study.
The survey measured HPV vaccine acceptability using five items assessing how willing a
participant would be to get HPV vaccine if it were approved for males (α=0.96). Response
options were ‘definitely not willing,’ ‘probably not willing,’ ‘not sure,’ ‘probably willing’
and ‘definitely willing.’ We classified each participant as either ‘willing to get HPV
vaccine’ (responded probably or definitely willing to three or more items) or ‘not willing to
get HPV vaccine.’
The survey measured HPV awareness by asking participants if they had ever heard of HPV
prior to the survey. We calculated an HPV knowledge score by summing correct responses
to nine individual items (each correct answer was one point) asked only of men who had
heard of HPV (figure 1). For analyses, we classified participants as ‘unaware of HPV’ if
they had never heard of HPV, aware of HPV with ‘low knowledge’ if they had heard of
HPV but answered four or less knowledge items correctly or aware with ‘high knowledge’ if
they had heard of HPV and answered at least five knowledge items correctly.
Men next received statements about HPV and HPV vaccine, although the software
prevented them from returning to HPV knowledge items. The provided statements addressed
HPV as being a common sexually transmitted infection (STI), diseases associated with HPV
and that a vaccine exists to protect women against cervical disease. A later statement
(provided prior to the willingness items) informed participants that HPV vaccine may also
provide health benefits to males. The survey assessed awareness of the vaccine by asking
participants if they had heard of it prior to the survey. Participants indicated whether they or
any family members or friends had ever received any doses of HPV vaccine. The survey
assessed whether participants had talked to a doctor about getting HPV vaccine for
themselves and if they thought their doctors would recommend they get the vaccine if it
were approved for males.
The survey measured perceived potential barriers (eg, cost, adverse effects) to obtaining
HPV vaccine using a four-item scale (possible range 1–5; α=0.68) with response options for
each item ranging from ‘not at all’ to ‘extremely.’ The survey assessed perceived
effectiveness of the vaccine against HPV-related disease (four items, possible range 1–5,
α=0.94) and perceived likelihood of getting HPV-related disease (four items, possible range
1–5, α=0.91) using multi-item scales. HPV-related diseases addressed in these scales were
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genital warts, anal cancer, oral cancer and penile cancer. Response options ranged from ‘no
protection’ to ‘complete protection’ for effectiveness items and ‘no chance’ to ‘certain I will
get [HPV-related disease]’ for likelihood items.
The survey also used multi-item scales to measure perceived knowledge of HPV-related
disease (three items, possible range 1–4, α=0.69), level of concern about getting HPV-
related disease (three items, possible range 1–4, α=0.51), perceived severity of HPV-related
disease (three items, possible range 1–4, α=0.73) and anticipated regret of not getting HPV
vaccine and later developing genital warts or an HPV infection that could lead to cancer
(two items, possible range 1–4, α=0.93). HPV-related diseases addressed in the perceived
knowledge, concern and perceived severity scales were genital warts, anal cancer and oral
cancer. Perceived knowledge response options ranged from ‘nothing at all’ to ‘quite a lot,’
while concern, perceived severity and anticipated regret items had response options ranging
from ‘not at all’ to ‘quite a lot.’
Participants provided information on demographic and health-related variables (table 1). We
defined ‘urban’ as living in a metropolitan statistical area and ‘rural’ as living outside of an
metropolitan statistical area.25
Data analysis
We excluded one man from all analyses who reported receiving HPV vaccine. We used
logistic regression models to examine bivariate correlates of HPV vaccine acceptability.
Statistically significant bivariate predictors (p<0.05) were entered into a multivariate logistic
regression model. We analysed unweighted data using SPSS version 16.0 (SPSS Inc.). All
statistical tests were two-tailed, using a critical α of 0.05.
RESULTS
Participant characteristics
The sample included men from all four geographic regions of the United States and
primarily from more urban areas (82%) (table 1). Most men were non-Hispanic white
(78%), married or living with a partner (67%), did not have a college degree (67%),
employed (80%), had health insurance (82%), non-smokers (75%) and had either not
received or were unsure if they had received one or more doses of hepatitis B vaccine
(76%). Some men (29%) had daughters in the approved age range for HPV vaccination
among females. A majority of men reported they had not initiated sex before age 16 y(76%)
and reported five or more lifetime sexual partners (58%). One participant each reported a
history of HIV infection and a history of cancer (oral, anal or penile) or lesions (anal or
penile). Few men reported a history of STIs other than HIV (11%).
HPV
Most men (61%) reported hearing of HPV prior to the survey, but HPV knowledge was low
among those who had (mean number of correct responses 3.5 out of 9.0, SD=2.2). Overall,
39% of men were unaware of HPV and 42% were aware but had low knowledge scores.
Most men knew that HPV is an STI (66%) and is a common infection (60%) (figure 1).
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However, less than half of participants (45%) knew that HPV causes health problems for
males, with even fewer knowing HPV can cause genital warts (34%) or cancer (oral cancer
21%, penile cancer=17%, anal cancer 14%).
Men perceived HPV-related disease to be severe (mean=3.24, SD=0.73), but they also
reported low levels of perceived knowledge about HPV-related disease (mean=1.51,
SD=0.48), concern about getting HPV-related disease (mean=1.30, SD=0.44) and perceived
likelihood of getting HPV-related disease (mean=1.89, SD=0.63).
HPV vaccine
Most men (63%) reported hearing of HPV vaccine prior to the survey. Almost half of
participants (47%) were unsure if their doctor would recommend they get HPV vaccine, if
licenced for males. Thirty-seven percent thought their doctor would not recommend they get
HPV vaccine, while only 16% thought their doctor would recommend the vaccine.
Participants reported moderate levels of perceived HPV vaccine effectiveness (mean=2.65,
SD=0.87) and barriers to getting HPV vaccine if it were available for males (mean=2.76,
SD=0.87). Participants reported fairly high levels of anticipated regret if they did not get
vaccinated and later got an HPV infection (mean=2.93, SD=1.05).
Eight men (3%) reported talking to a doctor previously about getting HPV vaccine for
themselves and 9% reported a family member or friend had been vaccinated. One man
reported trying to get HPV vaccine but could not since the doctor would not give the vaccine
to males.
Thirty-seven percent (109/296) of men were willing to receive HPV vaccine. In bivariate
analyses (tables 1 and 2), men were more willing to get the HPV vaccine if they were from
urban areas, either thought or were unsure if their doctor would recommend HPV vaccine,
were current smokers or reported five or more lifetime sexual partners (all p<0.05).
Willingness was lower among men who were married or living with their partner and those
who had either not heard of HPV prior to the survey or had heard of it but had low
knowledge (all p<0.05). Men willing to get vaccinated also reported higher levels of concern
about getting HPV-related disease, perceived likelihood of getting HPV-related disease,
perceived effectiveness of HPV vaccine or anticipated regret if they did not get vaccinated
and later became infected with HPV (all p<0.05). Acceptability was modest among younger
men aged 18–26 y (38%) and did not differ across age groups (p>0.05).
In multivariate analyses (tables 1 and 2), HPV vaccine acceptability was higher among men
from urban areas (OR 3.63, 95% CI 1.47 to 8.96) or if they either thought (OR 9.02, 95% CI
3.45 to 23.60) or were unsure (OR 2.67, 95% CI 1.30 to 5.47) if their doctor would
recommend they get vaccinated. Men reporting higher levels of perceived likelihood of
getting HPV-related disease (OR 1.80, 95% CI 1.02 to 3.17), perceived HPV vaccine
effectiveness (OR 1.86, 95% CI 1.22 to 2.83) or anticipated regret if they did not get
vaccinated and an HPV infection later developed (OR 2.01, 95% CI 1.40 to 2.89) were also
more willing to get vaccinated. Compared to participants with high HPV knowledge,
acceptability was lower among participants who had not heard of HPV (OR 0.41, 95% CI
0.18 to 0.97) and those with low knowledge (OR 0.27, 95% CI 0.11 to 0.64).
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HPV infection is common in men12 and can lead to negative health outcomes for infected
men and their sexual partners.467 However, nearly 40% of heterosexual men had not heard
of HPV prior to the survey. Among those who had heard of HPV, knowledge about HPV
infection was low as in previous research.1826 These findings indicate men need more
information about HPV and its potential health consequences.
Just over one-third of participants were willing to get HPV vaccine, similar to prior
estimates among adult men (33%–48%).1617 Numerous modifiable beliefs were correlated
with vaccine acceptability, including perceived likelihood of HPV-related disease, perceived
HPV vaccine effectiveness and anticipated regret. Participants’ thoughts regarding whether
their doctor would recommend they get HPV vaccine was also a strong correlate. A prior
study among heterosexual men also found that perceived likelihood was associated with
HPV vaccine acceptability,27 while we previously found correlates of vaccine acceptability
among gay and bisexual men included doctor’s recommendation, perceived vaccine
effectiveness and anticipated regret.21
In contrast to other studies among men,1828 we did not find a strong association between
number of lifetime sexual partners and HPV vaccine acceptability. This may be attributable
to most men (67%) being married or living with a partner. When we examined only men
who were not married or living with a partner in exploratory analyses, number of lifetime
sexual partners was not bivariately associated with vaccine acceptability (OR 1.03, 95% CI
0.45 to 2.38; p=0.941). This suggests that heterosexual men with lower likelihood of
previous HPV exposure may have similar levels of vaccine acceptability as men with higher
levels of past sexual activity.
The population-level benefit of vaccinating adult men against HPV is currently not known.
While the target group for HPV vaccination in males will likely be young adolescents
(assuming vaccine licensure for males occurs), adult men will still have to decide whether
‘off-label’ vaccination offers enough individual benefit to pay out-of-pocket for the vaccine.
Our findings are important because they provide early insight into factors that may affect
these decisions. These same factors also offer potential targets for future efforts to increase
informed HPV vaccination decision making among adult men, which may reduce
inappropriate demand and use of the vaccine. While this sample consisted mostly of men
outside the likely targeted age range for HPV vaccine in males, acceptability did not differ
with age. Results may, therefore, also provide a starting point for future research among
younger adolescent males.
We believe the strengths of this study are the use of a national sample, a high participation
rate and examining many constructs from the HPV vaccine acceptability literature. While
the study occurring before HPV vaccine licensure for males in the United States is a
potential limitation, the study timing is also a strength because results provide early
information on this important topic. HPV vaccine acceptability may overestimate behaviour
if the vaccine is approved for males. Although our sample was drawn from a study panel
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known to closely resemble the United States population on many demographic features,2930
most participants were non-Hispanic white and of high socioeconomic status.
Among a national sample of heterosexual men, we found low knowledge about HPV and
moderate HPV vaccine acceptability. Multiple modifiable beliefs were associated with
vaccine acceptability, providing insight into potentially important targets for future
communication and education messages targeted towards males to increase informed
decision-making regarding HPV vaccination. Additional research among males in the likely
targeted age range for HPV vaccination is needed to confirm our findings.
Acknowledgments
Funding American Cancer Society (MSRG-06-259-01-CPPB), the National Cancer Institute (R25 CA57726) and
the Investigator-Initiated Studies Program of Merck & Co, Inc.
References
1. Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: a systematic
review of the literature. J Infect Dis. 2006; 194:1044–57. [PubMed: 16991079]
2. Nielson CM, Harris RB, Dunne EF, et al. Risk factors for anogenital human papillomavirus
infection in men. J Infect Dis. 2007; 196:1137–45. [PubMed: 17955431]
3. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human
papillomavirus infections in a cohort of 290 US men. J Infect Dis. 2008; 198:827–35. [PubMed:
18657037]
4. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of
noncervical cancers in both men and women. Cancer. 2008; 113(10 Suppl):3036–46. [PubMed:
18980286]
5. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and
serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin
Microbiol. 1995; 33:2058–63. [PubMed: 7559948]
6. Bosch FX, Castellsague X, Munoz N, et al. Male sexual behavior and human papillomavirus DNA:
key risk factors for cervical cancer in Spain. J Natl Cancer Inst. 1996; 88:1060–7. [PubMed:
8683637]
7. Habel LA, Van Den Eeden SK, Sherman KJ, et al. Risk factors for incident and recurrent
condylomata acuminata among women. A population-based study. Sex Transm Dis. 1998; 25:285–
92. [PubMed: 9662761]
8. Food and Drug Administration. Gardasil (quadrivalent human papillomavirus types 6, 11, 16, 18).
Whitehouse Station (NJ): Merck & Co; Product approval information–licensing action [package
insert]. http://www.fda.gov/cber/label/HPVmer060806LB.pdf
9. Palefsky, J.; Giuliano, A. on behalf of the Male Quadrivalent HPV Vaccine Efficacy Trial Study
Group. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection
in young men. Abstract of presentation at the European Research Organization on Genital Infection
and Neoplasia (EUROGIN) International Multidisciplinary Conference; Nice, France. November
2008; http://www.eurogin.com
10. Giuliano, A.; Palefsky, J. on behalf of the Male Quadrivalent HPV Vaccine Efficacy Trial Study
Group. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of
HPV infection and HPV-related genital disease in young men. Abstract of presentation at the
European Research Organization on Genital Infection and Neoplasia (EUROGIN) International
Multidisciplinary Conference; Nice, France. November 2008; http://www.eurogin.com
11. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination
strategies. Emerg Infect Dis. 2007; 13:28–41. [PubMed: 17370513]
12. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs.
Emerg Infect Dis. 2004; 10:1915–23. [PubMed: 15550200]
Reiter et al. Page 7






















13. Gardner, A. FDA panel backs giving HPV vaccine Gardasil to young males. Sep 11. 2009 http://
abcnews.go.com/Health/Healthday/fda-panel-backs-giving-hpv-vaccine-gardasil-boys/story?
id=8531585
14. Hildesheim A, Herrero R. Human papillomavirus vaccine should be given before sexual debut for
maximum benefit. J Infect Dis. 2007; 196:1431–2. [PubMed: 18008218]
15. Jain N, Euler GL, Shefer A, et al. Human papillomavirus (HPV) awareness and vaccination
initiation among women in the United States, national immunization survey-adult 2007. Prev Med.
2009; 48:426–31. [PubMed: 19100762]
16. Ferris DG, Waller JL, Miller J, et al. Men’s attitudes toward receiving the human papillomavirus
vaccine. J Low Genit Tract Dis. 2008; 12:276–81. [PubMed: 18820541]
17. Lenselink CH, Schmeink CE, Melchers WJ, et al. Young adults and acceptance of the human
papillomavirus vaccine. Public Health. 2008; 122:1295–301. [PubMed: 18619631]
18. Jones M, Cook R. Intent to receive an HPV vaccine among university men and women and
implications for vaccine administration. J Am Coll Health. 2008; 57:23–32. [PubMed: 18682342]
19. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic
review. Prev Med. 2007; 45:107–14. [PubMed: 17628649]
20. Gilbert P, Brewer NT, Reiter PL, et al. HPV vaccine acceptability in heterosexual, gay, and
bisexual men. Working Paper. 2009
21. Reiter PL, Brewer NT, McRee AL, et al. Acceptability of HPV vaccine among a national sample
of gay and bisexual men. Sex Transm Dis. 2010; 37:197–203. [PubMed: 20118831]
22. Fazekas KI, Brewer NT, Smith JS. HPV vaccine acceptability in a rural southern area. J Womens
Health (Larchmt). 2008; 17:539–48. [PubMed: 18370586]
23. Keating KM, Brewer NT, Gottlieb SL, et al. Potential barriers to HPV vaccine provision among
medical practices in an area with high rates of cervical cancer. J Adolesc Health. 2008; 43(4
Suppl):S61–7. [PubMed: 18809147]
24. Reiter PL, Brewer NT, McRee AL, et al. Parents’ health beliefs and HPV vaccination of their
adolescent daughters. Soc Sci Med. 2009; 69:475–80. [PubMed: 19540642]
25. Office of Management and Budget. Standards for defining metropolitan and micropolitan statistical
areas; notice. Fed Regist. 2000; 65:82227–38. http://www.whitehouse.gov/omb/fedreg/
metroareas122700.pdf.
26. Gerend MA, Magloire ZF. Awareness, knowledge, and beliefs about human papillomavirus in a
racially diverse sample of young adults. J Adolesc Health. 2008; 42:237–42. [PubMed: 18295131]
27. Gerend MA, Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex
Transm Dis. 2009; 36:58–62. [PubMed: 18830138]
28. Ferris DG, Waller JL, Miller J, et al. Variables associated with human papillomavirus (HPV)
vaccine acceptance by men. J Am Board Fam Med. 2009; 22:34–42. [PubMed: 19124631]
29. Baker, LC.; Bundorf, MK.; Singer, S., et al. Validity of the survey of health and internet and
knowledge network’s panel and sampling. Updated 2003 http://www.cdc.gov/pcd/issues/
2004/oct/pdf/04_0004_01.pdf
30. Dennis, JM. Description of within-panel survey sampling methodology: the knowledge networks
approach. Updated 2009 http://www.knowlegenetworks.com/ganp/docs/KN%20Within-Panel
%20Survey20Sampling%20Methodology.pdf
Reiter et al. Page 8























• Human papillomavirus (HPV) vaccine acceptability among a national sample of
heterosexual men was moderate.
• Men had low knowledge about HPV, particularly concerning diseases associated
with persistent HPV infection.
• Modifiable beliefs associated with vaccine acceptability provide potential
targets for future efforts to increase informed decisions by men about HPV
vaccination.
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Human papillomavirus (HPV) knowledge among heterosexual men who had heard of HPV
prior to survey (n=182). Note. Correct answer is yes, except for items with superscript (*).
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Table 1
Categorical correlates of human papillomavirus (HPV) vaccine acceptability among heterosexual men (n=296)
No. willing to get HPV
vaccine/total no. in category (n
%) Bivariate OR (95% CI) Multivariate OR (95% CI)
Demographic characteristics
Age (y)
 18–26 13/34 (38) 1.17 (0.54 to 2.55) –
 27–45 49/126 (39) 1.21 (0.73 to 1.99) –
 46–59 47/136 (35) ref. –
Race/ethnicity
 White, non-Hispanic 79/230 (34) ref. –
 Other race/ethnicity 30/66 (45) 1.59 (0.91 to 2.78) –
Marital status
 Divorced, widowed, separated, never married 49/97 (51) ref. ref.
 Living with partner or married 60/199 (30) 0.42 (0.26 to 0.70)** 0.59 (0.31 to 1.12)
Parent of daughter aged 9–26 y†
 No 30/210 (38) ref. –
 Yes 29/86 (34) 0.83 (0.49 to 1.40) –
Education
 No college degree 76/197 (39) ref. –
 College degree 33/99 (33) 0.80 (0.48 to 1.32) –
Household income
 <$60000 52/147 (35) ref. –
 ≥$60000 57/149 (38) 1.13 (0.71 to 1.82) –
Employment status
 Not currently employed 18/58 (31) ref. –
 Currently employed 91/238 (38) 1.38 (0.74 to 2.54) –
Health insurance status
 No 18/52 (35) ref. –
 Yes 91/244 (37) 1.12 (0.60 to 2.10) –
Urbanicity
 Rural 12/54 (22) ref. ref.
 Urban 97/242 (40) 2.34 (1.17 to 4.67)* 3.63 (1.47 to 8.96)**
Geographic region
 Midwest 22/64 (34) ref. –
 Northeast 18/52 (35) 1.01 (0.47 to 2.18) –
 South 42/113 (37) 1.13 (0.60 to 2.15) –
 West 27/67 (40) 1.29 (0.63 to 2.62) –
HPV and HPV vaccine
Awareness and knowledge about HPV
 Never heard of HPV prior to survey 39/114 (34) 0.50 (0.26 to 0.96)* 0.41 (0.18 to 0.97)*






















Reiter et al. Page 12
No. willing to get HPV
vaccine/total no. in category (n
%) Bivariate OR (95% CI) Multivariate OR (95% CI)
 Heard of HPV, low knowledge 41/125 (33) 0.47 (0.25 to 0.89)* 0.27 (0.11 to 0.64)**
 Heard of HPV, high knowledge 29/57 (51) ref. ref.
Heard of HPV vaccine prior to survey
 No 39/110 (35) ref. –
 Yes 70/186 (38) 1.10 (0.67 to 1.79) –
Family member or friend has gotten HPV vaccine
 No 99/268 (37) ref. –
 Yes 10/28 (36) 0.95 (0.42 to 2.14) –
Think doctor would recommend HPV vaccine
 No 19/110 (17) ref. ref.
 Don’t know 58/139 (42) 3.43 (1.89 to 6.24)** 2.67 (1.30 to 5.47)**
 Yes 32/47 (68) 10.22 (4.65 to 22.46)** 9.02 (3.45 to 23.60)**
Health and health behaviours
Smoking status
 Non-smoker 71/221 (32) ref. ref.
 Smoker 38/75 (51) 2.17 (1.27 to 3.70)** 1.32 (0.67 to 2.60)
Hepatitis B vaccination history
 No doses received/Don’t know 78/225 (35) ref. –
 At least one dose received 31/71 (44) 1.46 (0.85 to 2.52) –
Age at first sexual intercourse (y)
 <16 29/71 (41) 1.25 (0.73 to 2.16) –
 ≥16 80/225 (36) ref. –
Number of lifetime sexual partners
 <5 35/123 (29) ref. ref.
 ≥5 74/173 (43) 1.88 (1.15 to 3.08)* 1.45 (0.76 to 2.74)
Prior STI diagnosis (other than HIV)
 No 93/263 (35) ref. –
 Yes 16/33 (48) 1.72 (0.83 to 3.56) –
The multivariate model included variables from tables 1 and 2 bivariately associated (p<0.05) with willingness to get HPV vaccine. The
multivariate model did not include variables with dashes (−). History of HIV infection and prior diagnosis of cancer or lesions were not examined






Approved age range for HPV vaccine for females in the United States.
HPV, human papillomavirus; ref., referent group; STI, sexually transmitted infection.
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Table 2
Continuous correlates of human papillomavirus (HPV) vaccine acceptability among heterosexual men (n=296)
Mean (SD)
Bivariate OR (95% CI) Multivariate OR (95% CI)Not willing (n=187) Willing (n=109)
Perceived knowledge of HPV-related
disease
1.50 (0.50) 1.54 (0.46) 1.19 (0.73 to 1.93) –
Concern about getting HPV-related
disease
1.21 (0.38) 1.45 (0.51) 3.53 (1.93 to 6.46)** 1.64 (0.79 to 3.41)
Perceived severity of HPV-related
disease
3.23 (0.75) 3.27 (0.70) 1.08 (0.78 to 1.50) –
Perceived likelihood of getting HPV-
related disease
1.74 (0.61) 2.15 (0.57) 3.07 (2.00 to 4.71)** 1.80 (1.02 to 3.17)*
Perceived barriers to getting HPV
vaccine
2.71 (0.89) 2.86 (0.83) 1.21 (0.92 to 1.59) –
Perceived effectiveness of HPV vaccine 2.43 (0.85) 3.02 (0.78) 2.37 (1.72 to 3.27)** 1.86 (1.22 to 2.83)**
Anticipated regret if chose not to get
vaccinated and later developed HPV
infection
2.62 (1.07) 3.46 (0.78) 2.54 (1.89 to 3.41)** 2.01 (1.40 to 2.89)**
The multivariate model included variables from tables 1 and 2 bivariately associated (p<0.05) with willingness to get HPV vaccine. The
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